Monoclonal antibodies (mAbs) have become some of the most important drugs in modern medicine, with applications spanning cancer, autoimmune disease, infectious disease, neurology, and gastroenterology. But while their clinical value is well established, producing them at large scale remains a technically demanding and highly regulated process. A new review examines how good manufacturing practice (GMP) standards govern every stage of mAb production – and why manufacturing is still one of the biggest barriers to broader access.
The review walks through the full production chain, from cell-line development to purification, formulation, and quality control. In most cases, therapeutic mAbs are produced in mammalian cells, especially Chinese hamster ovary (CHO) cells, because these systems can generate the complex post-translational modifications needed for functional antibodies. Once stable producer cell lines are established, manufacturers build master and working cell banks to preserve consistency, then scale cultures from small flasks into industrial bioreactors under tightly controlled conditions. Parameters such as pH, dissolved oxygen, temperature, nutrient supply, and metabolite buildup must all be closely monitored, because even relatively small shifts can affect antibody yield and quality.
Purification is just as critical. After harvest, antibodies must be separated from host cell proteins, DNA, aggregates, and other process-related impurities. Protein A affinity chromatography remains the standard first capture step, often followed by additional chromatographic polishing, viral clearance, ultrafiltration, and diafiltration. The result is then formulated with stabilizing excipients and prepared for storage, usually under refrigerated or frozen conditions. Because antibodies are sensitive to temperature shifts and freeze-thaw damage, maintaining the cold chain becomes an essential part of GMP compliance, not just a logistical detail.
The article also emphasizes that GMP is about much more than sterile rooms and paperwork. It depends on a broader pharmaceutical quality system that links staff training, equipment qualification, environmental monitoring, process validation, and data integrity. Regulators now expect manufacturers to demonstrate monoclonality in production cell lines, validate aseptic processes with repeated media fills, and maintain traceable records that meet ALCOA principles – data must be attributable, legible, contemporaneous, original, and accurate. In practice, this means every batch must be supported by a dense trail of validated procedures and documented evidence.
Even with these systems in place, major challenges remain. Manufacturing costs are still high, particularly when chemically defined media, perfusion systems, and multiple purification steps are required. Scaling up from research-grade production to industrial GMP manufacturing is another persistent pain point, especially when a process behaves differently in large bioreactors than it did at laboratory scale. Batch-to-batch variability, contamination risks, and evolving regulatory expectations add further pressure. And as outsourcing to contract development and manufacturing organizations becomes more common, maintaining consistent GMP oversight across multiple partners grows more difficult.
The review points to several technologies that could ease some of these pressures. Continuous bioprocessing, AI-assisted process control, advanced analytics, and real-time monitoring tools are all being explored as ways to improve productivity and reduce variability. Blockchain and digital traceability systems may also strengthen supply-chain transparency, particularly for sensitive biologics that depend on tight cold-chain control. But adopting these tools in a regulated GMP setting is slow work, requiring fresh rounds of validation and regulatory scrutiny.
The overall message is clear: monoclonal antibodies are no longer limited by therapeutic promise, but by the difficulty of making them reliably, affordably, and at scale. As demand continues to grow, the future of the field will depend not only on discovering new antibody targets, but on building manufacturing systems robust enough to deliver them worldwide.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
